Given that CDH17-targeting CDH17-CAR-NK92 therapy showed excellent anti-tumor activity in the CDX model, we next investigated whether CDH17-CAR-NK92 therapy could obtain similar results in a PDX model. Here, CDH17 is linked to neoplasm.